Γ

F Toia, A B Di Stefano, S Meraviglia, E Lo Presti, R Pirrello, G Rinaldi, F Fulfaro, F Dieli, A Cordova

Abstract readReview

In one paragraph

Review in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.Journal for immunotherapy of cancer · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

F ToiaDepartment of Surgical, Oncological and Oral Sciences, Plastic and Reconstructive Surgery Section, University of Palermo, 90127, Italy.ORCID 0000-0003-4903-815X

A B Di StefanoDepartment of Surgical, Oncological and Oral Sciences, Plastic and Reconstructive Surgery Section, University of Palermo, 90127, Italy.ORCID 0000-0003-4323-8564

S MeravigliaDepartment of Biopathology, Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127, Italy.

E Lo PrestiDepartment of Biopathology, Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127, Italy.

R PirrelloDepartment of Surgical, Oncological and Oral Sciences, Plastic and Reconstructive Surgery Section, University of Palermo, 90127, Italy.

G RinaldiDepartment of Surgical, Oncological and Oral Sciences, Oncology Section, University of Palermo, 90127, Italy.

F FulfaroDepartment of Surgical, Oncological and Oral Sciences, Oncology Section, University of Palermo, 90127, Italy.

F DieliDepartment of Biopathology, Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR), University of Palermo, 90127, Italy.

A CordovaDepartment of Surgical, Oncological and Oral Sciences, Plastic and Reconstructive Surgery Section, University of Palermo, 90127, Italy.ORCID 0000-0002-2752-4897

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic melanoma is still associated with a poor prognosis, and there is increasing interest in immunotherapy alone or in combination with other adjuvant therapies. Γ

Identifiers

PMID31239842

DOI10.1155/2019/9014607

PMCPMC6556315

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.